FP59-FR-02 Predictive Factors for Postthymectomy Myasthenic Crisis in Patients with Myasthenia GravisT.S. NamElsevier Science2009DOI 10.1016/s0022-510x(09)70582-9
FP59-FR-05 Genetic Factors in Myasthenia Gravis and Lambert-Eaton Myasthenic SyndromeM.J. TitulaerElsevier Science2009DOI 10.1016/s0022-510x(09)70585-4
FP59-FR-01 Factors Associated with Response to Calcineurin Inhibitors in Myasthenia GravisY. NaganeElsevier Science2009DOI 10.1016/s0022-510x(09)70581-7
FP59-FR-03 Serological Diagnosis of MG in Tianjin, China, with Non-radioactive Assays for AChR and MuSK AntibodiesL. YangElsevier Science2009DOI 10.1016/s0022-510x(09)70583-0
FP59-FR-04 Clinical Efficacy, T/B Cell Subtypes and Cytokine Modulating Effects of Tacrolimus in Generalized Myasthenia GravisC.B. ZhaoElsevier Science2009DOI 10.1016/s0022-510x(09)70584-2
FP59-FR-06 Clinical and Serological Study of Myasthenia Gravis in a South Asian Population Using Both Radioimmunoprecipitation and Cell-based AssaysT. ChangElsevier Science2009DOI 10.1016/s0022-510x(09)70586-6
Fp592factors Associated To Ultrafiltrafiltration In Peritoneal DialysisStachowska-Pietka, JoannaOxford University Press2015DOI 10.1093/ndt/gfv180.44
Fp594targeting Microbiota Derived Uremic Retention Solutes With AntibioticsPoesen, RubenNephrology Dialysis Transplantation2015DOI 10.1093/ndt/gfv180.46
Fp594does Peritoneal Dialysis Affect Bioimpedance-based Volume Estimation?Schneditz, DanielOxford University Press2019DOI 10.1093/ndt/gfz106.fp594
Fp599vitamin D Therapy And Mortality In Hemodialysis PatientsVilla-Bellosta, RicardoOxford University Press2018DOI 10.1093/ndt/gfy104.fp599